Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 12/20 | 0.69 |
| ▸ | HTR2C | P28335 | 12/20 | 0.69 |
| ▸ | DRD2 | P14416 | 12/20 | 0.69 |
| ▸ | HTR6 | P50406 | 3/20 | 0.49 |
| ▸ | DRD4 | P21917 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | HTR1D | P28221 | 1/20 | 0.42 |
| ▸ | HTR1B | P28222 | 1/20 | 0.42 |
| ▸ | HTR1F | P30939 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24243724 | 0.84 | HTR2A (0.57) | HTR2AHTR2CDRD2HTR6DRD4 | |
| SCHEMBL24243712 | 0.81 | HTR6 (0.74) | HTR2AHTR2CDRD2HTR6CYP3A4 | |
| SCHEMBL24643502 | 0.79 | HTR2A (0.68) | HTR2AHTR2CDRD2HTR6DRD4 | |
| SCHEMBL24243720 | 0.79 | HTR2A (0.72) | HTR2AHTR2CDRD2HTR6DRD4 | |
| SCHEMBL24243704 | 0.79 | HTR2A (0.69) | HTR2AHTR2CDRD2HTR6DRD4 | |
| SCHEMBL24243688 | 0.79 | HTR2A (0.69) | HTR2AHTR2CDRD2HTR6DRD4 | |
| SCHEMBL13267812 | 0.78 | DRD2 (0.51) | HTR2AHTR2CDRD2HTR6DRD4 | |
| SCHEMBL9285803 | 0.78 | KDM4E (0.54) | HTR2AHTR2CDRD2HTR6DRD4 | |
| SCHEMBL24243771 | 0.76 | HTR2A (0.67) | HTR2AHTR2CDRD2HTR6DRD4 | |
| SCHEMBL16297142 | 0.72 | DRD2 (0.46) | HTR2AHTR2CDRD2HTR6DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220241243-A1 | METHODS OF TREATING MOOD DISORDERS | GILGAMESH PHARMACEUTICALS, INC. | 2022-08-04 | — | — | US | disclosed |
| US-20220041551-A1 | METHODS OF TREATING MOOD DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220041551-A1 | METHODS OF TREATING MOOD DISORDERS | GRIN2C, GRIN2A, TPH2 | HTR2A 5/4885HTR2C 4/4885DRD2 105/4885 |
| US-20220241243-A1 | METHODS OF TREATING MOOD DISORDERS | GRIN2C, GRIN2A, TPH2 | HTR2A 5/4885HTR2C 4/4885DRD2 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.